Ann: Dr Irminger steps down from Board, continues as Consultant, page-10

@morgenlofting....good post with good points. However I don't think that the Bard 1 test kits will die as a result of ego...the thing that will sink it will be a rival product that is similar arriving to market prior to Bard 1 or if the clinical validation trial at Griffith throws up a clanger. I agree that whilst HTert is providing some much needed cash flow, the "Sienna" people could have a greater say although this is pure speculation, but once the Bard 1 test kit is commercialised the networks and sales avenues selling the hTert product may provide a key "doorway" into the medical sales market. It is a huge growth area with keen competition ie Rhythm Biosciences have a good potential product as do many others, but the science behind the bard 1 testing sounds brilliant and no doubt has the potential to change testing in particular early detection dramatically ie disruptive technology and science, thus it will be how the wider market perceives the products and subsequently how that translates into sales. It will be really fascinating to see this company in 12 months to look at any progression, financial status and therefore share price to see how the management have addressed the market opportunities with the correct strategies assuming the Bard 1 test kits have gone to market. Take care